BPC-157: The Most Studied Healing Peptide
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a segment of a protein found in human gastric juice. Since its initial characterization by researchers at the University of Zagreb in the early 1990s, BPC-157 has been the subject of over 40 published research studies spanning tissue repair, gastrointestinal protection, neuroprotection, and vascular biology.
This article reviews the published scientific literature on BPC-157, organized by research area, with PubMed citations for every claim. All statements reflect published research findings — not therapeutic claims.
Molecular Profile
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Amino acids: 15 (pentadecapeptide)
- Molecular weight: ~1419.53 Da (acetate salt form)
- CAS number: 137525-51-0
- Origin: Partial sequence from human gastric juice protein BPC
- Stability: Notably stable in gastric acid conditions — unusual for a peptide
Research Area 1: Tissue Repair and Wound Healing
The largest body of BPC-157 research examines its effects on tissue repair across multiple tissue types.
Tendon and Ligament Repair
Chang et al. (2011) demonstrated that BPC-157 promoted tendon healing in a rat Achilles tendon transaction model. The study observed increased tendon-to-bone healing, enhanced collagen organization, and improved biomechanical properties in BPC-157-treated groups compared to controls.
Staresinic et al. (2006) reported that BPC-157 accelerated healing of transected quadriceps muscle in rats, with improved functional recovery as measured by biomechanical testing.
Muscle Repair
Pevec et al. (2010) studied BPC-157's effects on muscle healing after crush injury in rats. The research demonstrated faster recovery of muscle function and reduced inflammatory infiltration in treated groups.
Bone Healing
Sebecic et al. (1999) investigated BPC-157's effects on bone healing in a rabbit segmental bone defect model. Results indicated enhanced new bone formation in the BPC-157 group.
Skin Wound Healing
Sikiric et al. (2006) reviewed evidence showing BPC-157 accelerated skin wound closure in multiple rodent models, with effects on angiogenesis and collagen deposition.
Research Area 2: Gastrointestinal Protection
Given its gastric juice origin, BPC-157's GI effects have been extensively studied.
Gastric Ulcer Healing
Sikiric et al. (2018) published a comprehensive review in Current Pharmaceutical Design documenting BPC-157's gastroprotective effects across multiple ulcer models (ethanol-induced, NSAID-induced, cysteamine-induced). The peptide demonstrated consistent anti-ulcer activity across all models tested.
Inflammatory Bowel Models
Research published by Sikiric et al. (2013) showed BPC-157 reduced inflammation and improved mucosal healing in experimental colitis models in rats. The effects were observed with both systemic and local (oral) administration.
Esophageal Lesions
Gjurasin et al. (2001) reported that BPC-157 promoted healing of esophageal lesions in rats, supporting the compound's broad GI protective profile.
Oral Bioavailability
Notably, BPC-157 has demonstrated biological activity via oral administration in multiple published studies — an unusual property for a peptide, attributed to its stability in acidic gastric conditions. This has made oral delivery a significant area of ongoing research interest.
Research Area 3: Angiogenesis and Vascular Effects
Blood Vessel Formation
Hsieh et al. (2017) demonstrated that BPC-157 promoted angiogenesis in a chicken chorioallantoic membrane (CAM) model and in rat wound healing studies. The research suggested involvement of the VEGF (vascular endothelial growth factor) pathway.
Vascular Healing
Seiwerth et al. (2014) published research showing BPC-157's effects on blood vessel repair following surgical transection in rats, with improved anastomosis patency and reduced thrombosis.
Nitric Oxide System
Multiple studies have documented BPC-157's interaction with the nitric oxide (NO) system. Sikiric et al. (2014) proposed that BPC-157 modulates the L-arginine/NO pathway, which may underlie several of its observed biological effects including vasodilation, anti-inflammatory activity, and tissue protection.
Research Area 4: Neuroprotection
Central Nervous System
Tudor et al. (2010) examined BPC-157's effects in traumatic brain injury models in rats. The research reported reduced brain edema, decreased neurological deficits, and improved recovery compared to control groups.
Peripheral Nerve Repair
Gjurasin et al. (2010) investigated BPC-157's effects on sciatic nerve transection in rats. Results showed improved nerve regeneration and functional recovery in treated animals.
Dopaminergic System
Sikiric et al. (2016) published research on BPC-157's interactions with the dopaminergic system, documenting effects on dopamine receptor expression and potential relevance to dopamine-related research models.
Research Area 5: Anti-Inflammatory Mechanisms
Seiwerth et al. (2014) reviewed evidence that BPC-157 modulates inflammatory mediators including prostaglandins, cytokines, and the nitric oxide system. The anti-inflammatory effects appear to contribute to the compound's tissue-protective properties across multiple organ systems.
Hsieh et al. (2020) further explored the molecular pathways involved, identifying potential roles for the FAK-paxillin signaling pathway and connections to growth factor modulation.
Proposed Mechanisms of Action
Based on the cumulative published evidence, BPC-157 appears to work through several interconnected mechanisms:
- NO system modulation: Interaction with the L-arginine/nitric oxide pathway, affecting vasodilation and tissue perfusion
- Growth factor signaling: Modulation of VEGF, EGF, and other growth factors involved in tissue repair
- FAK-paxillin pathway: Activation of focal adhesion kinase signaling, important for cell migration and wound healing
- Anti-inflammatory activity: Modulation of prostaglandins and inflammatory cytokines
- Angiogenesis promotion: Stimulation of new blood vessel formation, supporting oxygen and nutrient delivery to healing tissues
Research Limitations and Context
Important context for interpreting BPC-157 research:
- Animal models predominate: The vast majority of published BPC-157 research has been conducted in rats, mice, and other animal models. Human clinical trial data is limited.
- Zagreb research group: A significant proportion of BPC-157 publications originate from the University of Zagreb group led by Predrag Sikiric. While the research has been published in peer-reviewed journals, independent replication by other research groups would strengthen the evidence base.
- Dose extrapolation: Published dosing ranges are in micrograms per kilogram of body weight in animal models. Direct extrapolation to human-equivalent doses requires careful consideration of species-specific pharmacokinetics.
- No FDA-approved indications: BPC-157 has not completed human clinical trials required for FDA approval and is classified for research use only.
BPC-157 in Combination Research
Several studies have examined BPC-157 in combination with other compounds:
BPC-157 + TB-500
While no published study has directly compared the combination to either compound alone, the theoretical rationale is based on complementary mechanisms: BPC-157's NO/VEGF-mediated angiogenesis and TB-500's actin-regulation-mediated cell migration. BeaCapra offers these as The Foundation Stack for researchers exploring this combination.
BPC-157 + NSAIDs
Sikiric et al. (2018) documented that BPC-157 counteracted NSAID-induced gastric damage in multiple models, suggesting a protective role against NSAID-related tissue toxicity.
Key Published References
- Sikiric P et al. "Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract." Curr Pharm Des. 2018;24(18):1990-2001.
- Seiwerth S et al. "BPC 157's effect on healing." J Physiol Pharmacol. 2014;65(5):601-623.
- Chang CH et al. "BPC-157 enhances tendon-to-bone healing." J Orthop Res. 2011;29(10):1514-1519.
- Hsieh MJ et al. "BPC-157 enhances the growth of fibroblasts, tendon, and the healing of wounds." Life Sci. 2017;175:52-57.
- Tudor M et al. "BPC 157 and traumatic brain injury." Regul Pept. 2010;160(1-3):26-32.
- Pickart L et al. "Tripeptide GHK-Cu and tissue remodeling." J Biomater Sci Polym Ed. 2012;23(8):1015-1034.
Frequently Asked Questions
How many studies have been published on BPC-157?
Over 40 peer-reviewed studies have been published on BPC-157, spanning tissue repair, GI protection, neuroprotection, angiogenesis, and anti-inflammatory effects. The majority have been published in journals such as Life Sciences, Journal of Physiology and Pharmacology, and Current Pharmaceutical Design.
Has BPC-157 been tested in humans?
Published human clinical trial data for BPC-157 is limited. The majority of research has been conducted in animal models (primarily rats). While the animal data is extensive, human pharmacokinetic and efficacy data remains an area for future research.
What is the typical research dose for BPC-157?
Published animal studies typically use doses in the range of 10 mcg/kg to 200 mcg/kg body weight, administered via subcutaneous injection or oral administration. These are animal research doses — human-equivalent dosing requires species-specific pharmacokinetic conversion.
Is BPC-157 stable in stomach acid?
Yes. One of BPC-157's most notable properties is its stability in acidic conditions, consistent with its origin from gastric juice protein. This property has enabled research on oral administration routes, which is unusual for peptide compounds.
Where can I find research-grade BPC-157?
BeaCapra offers research-grade BPC-157 with 99%+ HPLC purity, batch-specific COAs, mass spectrometry verification, and the industry's only subscribe-and-save program for ongoing research protocols. Available as an individual compound or as part of The Foundation Stack with TB-500.